Somewhat Positive News Coverage Somewhat Unlikely to Affect Celldex Therapeutics (CLDX) Stock Price

Press coverage about Celldex Therapeutics (NASDAQ:CLDX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.0390377764121 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Celldex Therapeutics (CLDX) opened at $2.80 on Friday. The stock has a market capitalization of $380.76, a price-to-earnings ratio of -2.77 and a beta of 2.73. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.94.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.07. The business had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The business’s revenue for the quarter was up 77.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.29) EPS. equities analysts predict that Celldex Therapeutics will post -0.93 earnings per share for the current year.

CLDX has been the topic of several recent research reports. WBB Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, BidaskClub raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Celldex Therapeutics has a consensus rating of “Hold” and a consensus price target of $7.05.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Celldex Therapeutics (CLDX) Stock Price” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-celldex-therapeutics-cldx-stock-price.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit